Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Abstract

BACKGROUND/AIMS There is increasing evidence demonstrating the value of transfusions in sickle cell disease (SCD). However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that can negatively impact quality of life and adherence to treatment. METHODS As part of a phase II… (More)
DOI: 10.1159/000125550

Topics

Cite this paper

@article{Vichinsky2008PatientreportedOO, title={Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.}, author={Elliott P. Vichinsky and Zahra Pakbaz and Onyinye C Onyekwere and John Porter and Paul Swerdlow and Thomas Elliot Coates and Peter Lane and Beatrice A Files and Brigitta U. Mueller and L{\'e}na Co{\"i}c and Gian Luca Forni and Roland Fischer and Peter Marks and Diana Rofail and Linda N. Abetz and Jean-François Baladi}, journal={Acta haematologica}, year={2008}, volume={119 3}, pages={133-41} }